Literature DB >> 29079171

A novel fusion gene CRTC3-MAML2 in hidradenoma: histopathological significance.

Yuki Kuma1, Yuichi Yamada2, Hidetaka Yamamoto2, Kenichi Kohashi2, Takamichi Ito1, Masutaka Furue3, Yoshinao Oda4.   

Abstract

Hidradenoma usually presents as a solitary, slow-growing, and solid or cystic nodular lesion, which arises in various anatomical sites. Its diagnosis is occasionally difficult because the tumor shares histological features with other cutaneous appendage tumors. Recently, CRTC1-MAML2 fusion gene was reported in hidradenomas, with the fusion transcript being demonstrated in approximately 50% of cases. However, limited information is available regarding its clinical significance. Here, we investigated the relationship between the fusion gene and clinicohistopathological features. We reviewed 39 cases histologically diagnosed as hidradenoma. Reverse-transcription polymerase chain reaction (RT-PCR) was performed for all 39 cases, and fluorescence in situ hybridization was also performed for the RT-PCR-negative cases. The 39 tumors included 36 clear cell hidradenomas and 3 poroid hidradenomas. The details of the cellular components were as follows: clear cell-dominant type, 9 cases; polygonal cell-dominant type, 21 cases; and equally mixed type, 9 cases. There were no tumors with apparent mucinous cells. There were 8 tumors with prominent cystic change, 2 of which presented apocrine-like decapitated secretion. CRTC1-MAML2 fusion was detected in 10 of the 39 tumors (26%) and CRTC3-MAML2 fusion in 2 of the 39 (5%) by RT-PCR. MAML2 gene rearrangement was detected in 11 of 27 fusion gene-negative cases by fluorescence in situ hybridization. Moreover, neither the fusion genes nor gene rearrangement was detected in prominent cystic tumors and poroid hidradenomas. We conclude that CRTC1/3-MAML2 fusion gene analysis can be a useful method for diagnosing hidradenoma. Considering the histological and genetic similarity to mucoepidermoid carcinoma, hidradenoma may be a cutaneous counterpart of salivary gland mucoepidermoid carcinoma.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRTC1; CRTC3; Fusion gene; Hidradenoma; MAML2; Mucoepidermoid carcinoma

Mesh:

Substances:

Year:  2017        PMID: 29079171     DOI: 10.1016/j.humpath.2017.10.004

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas.

Authors:  May P Chan; Komal R Plouffe; Chia-Jen Liu; Nallasivam Palanisamy; Shannon Carskadon; Lili Zhao; Rosalynn M Nazarian; Alison B Durham; Timothy M Johnson; Aleodor A Andea; Rajiv M Patel; Lori Lowe; Douglas R Fullen; Noah A Brown; Scott A Tomlins; Aaron M Udager; Paul W Harms
Journal:  Mod Pathol       Date:  2019-12-19       Impact factor: 7.842

2.  MAML2-Rearranged Mucoepidermoid Carcinoma of the Parotid Gland: A Report in a 20-Month-Old Toddler.

Authors:  Adepitan A Owosho; Abiodun S Olatunji; Adewale F Adejobi; Olawumi A Fatusi; Toluwaniyin Okunade; Kelly Maddux; Justin Shaw; Kurt F Summersgill
Journal:  Case Rep Dent       Date:  2022-03-29

3.  Effects of the MAML2 genetic variants in glioma susceptibility and prognosis.

Authors:  Ming Zhang; Yonglin Zhao; Junjie Zhao; Tingqin Huang; Xiaoye Guo; Xudong Ma; Yuan Wu
Journal:  Biosci Rep       Date:  2019-10-30       Impact factor: 3.840

4.  Genetic variant of MAML2 in the NOTCH signaling pathway and the risk of bladder cancer: A STROBE-compliant study.

Authors:  Yang Shen; Qian Lu; Hesong Ye; Zhonglei Deng; Long Ma; Qingling Zhang; Jingyuan Tang; Lin Yuan
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.